Key takeaways

  • Shares in the company were trading up 9.40% at A$2.56 on 23 July 2026.
  • The company's lead diagnostic, 64Cu-SAR-bisPSMA, is a next-generation PSMA PET imaging agent targeting the multi-billion-dollar prostate-cancer imaging market.
  • In April 2026, Clarity signed a Commercial Manufacturing Agreement with Nucleus RadioPharma covering US production and distribution of 64Cu-SAR-bisPSMA.
  • Two registrational Phase III trials, CLARIFY (pre-prostatectomy) and AMPLIFY (biochemical recurrence), are intended to support a US FDA marketing application.
  • On 16 July 2026, Clarity announced that Allison Rossiter, a senior healthcare executive with commercial leadership experience, had joined its board as an independent Non-Executive Director.

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals Ltd (ASX:CU6) moved sharply higher on 23 July 2026, with shares trading up 9.40% to A$2.56 as investors focused on the company's accelerating commercialisation pathway for its lead asset, SAR-bisPSMA. Clarity is developing the copper-64 labelled imaging agent as a next-generation PSMA PET diagnostic targeting the multi-billion-dollar prostate-cancer imaging market, and has been advancing two registrational trials — CLARIFY and AMPLIFY — intended to underpin a US FDA marketing application. A US manufacturing and distribution agreement with Nucleus RadioPharma, signed ahead of potential commercialisation, has added a concrete supply-chain dimension to a program that investors increasingly view as a credible near-term revenue opportunity in the rapidly growing nuclear medicine sector.

The development in focus: commercialisation moving closer

Clarity Pharmaceuticals is a radiopharmaceutical company that designs targeted copper-based products, using its proprietary chelator technology, for imaging and treating cancer. Its most advanced asset is SAR-bisPSMA, which binds to prostate-specific membrane antigen (PSMA), a protein commonly over-expressed in prostate cancer cells. SAR-bisPSMA exists in two forms: a diagnostic imaging version using copper-64 (64Cu) and a therapeutic version using copper-67 (67Cu). The isotopes share the same targeting molecule, an approach the company describes as a matched "theranostic" pairing.

The theme underpinning recent investor interest is the transition from clinical development toward commercialisation of the diagnostic product. A company announcement lodged with the ASX on 16 July 2026 explicitly framed 64Cu-SAR-bisPSMA as a "best-in-class next-generation diagnostic" positioned to advance the PSMA PET imaging market, noting that the market "remains dominated by products with such low sensitivity" and that the candidate "continues to demonstrate exceptional efficacy" with "strong and growing data supporting commercialisation pathways in the US."

That 16 July announcement itself concerned a governance change: the appointment of Allison Rossiter as an independent Non-Executive Director. The appointment expanded the board to six members, comprising two Executive Directors and four Non-Executive Directors, establishing an independent-director majority. Ms Rossiter brings around 25 years of healthcare leadership experience across diagnostics, pharmaceuticals and medical technology, including prior senior roles at Roche across three divisions, a role at an ASX-listed diagnostics company, and most recently Country President for Novartis in Australia and New Zealand. Her qualifications include a BSc in Computing and Informatics and an MBA from Oxford's Saïd Business School.

While a board appointment is a corporate-governance event rather than a clinical or commercial catalyst on its own, the accompanying commentary positioned the addition of senior commercial healthcare experience as relevant to Clarity's commercialisation ambitions.

Manufacturing and supply: the Nucleus RadioPharma agreement

A central plank of any radiopharmaceutical commercialisation plan is reliable, large-scale manufacturing, because copper-64 has a limited half-life and doses must be produced and delivered on a tight timeframe. On 14 April 2026, Clarity announced a Commercial Manufacturing Agreement with US-based Nucleus RadioPharma to manufacture and distribute 64Cu-SAR-bisPSMA.

Under the arrangement, an existing facility in Rochester, Minnesota, is described as capable of producing approximately 50,000 patient doses annually. A planned 47,000-square-foot facility in Spring House, Pennsylvania, is slated to open in 2028 with projected capacity of up to 600,000 doses per year. Together, the facilities are intended to enable manufacturing and distribution across all 50 US states and select international sites, including Europe. The agreement expands a relationship that began in November 2024 with a Master Services Agreement covering clinical supply of the therapeutic 67Cu-SAR-bisPSMA.

Nucleus RadioPharma chief executive Stephen Hahn was quoted describing 64Cu-SAR-bisPSMA as "quickly approaching its market launch," and referencing data highlighting detection benefits compared with standard-of-care PSMA PET. Specific commercial terms of the agreement, including pricing, were not disclosed beyond a reference to cancellation and extension provisions aligned with industry-standard rates.

Registrational trials underpinning the FDA pathway

Clarity's US regulatory strategy for the diagnostic rests on two registrational Phase III trials.

The CLARIFY trial (ClinicalTrials.gov identifier NCT06056830) is designed to recruit 383 participants across sites in the United States and Australia. It evaluates 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy, assessing the agent's performance in detecting regional nodal metastasis. A distinguishing feature is imaging at two timepoints, on the day of administration and again approximately 24 hours later, a delayed-imaging capability the company attributes to the candidate's design. The trial commenced in late 2023.

The AMPLIFY trial (NCT06970847) is a non-randomised, single-arm, open-label, multi-centre study of 64Cu-SAR-bisPSMA PET in patients with biochemical recurrence of prostate cancer, defined as rising PSA above 0.2 ng/mL after initial definitive treatment. It targeted approximately 220 participants. Clarity has reported that the trial consented in excess of its planned number of participants, with new enrolment halted pending completion of remaining screening assessments, and that its enrolment target was achieved in March 2026. As with CLARIFY, results are intended to support a US FDA marketing application.

Separately, Clarity has previously reported receiving US FDA Fast Track designations relating to SAR-bisPSMA, including for the diagnostic in biochemical recurrence imaging and for the copper-67 therapeutic candidate in metastatic castration-resistant prostate cancer. Fast Track designation is a process intended to facilitate development and expedite review of therapies addressing serious conditions, but it is not a guarantee of approval. The company has also flagged that clinical data on SAR-bisPSMA was scheduled for presentation at the European Association of Nuclear Medicine (EANM) congress in 2026.

Potential opportunities and positive factors

Several verified elements support the constructive thesis some investors hold for Clarity. The company is targeting the sizeable and growing PSMA PET imaging market for prostate cancer, one of the most common cancers in men. Its diagnostic candidate has advanced through two registrational Phase III trials, both of which have progressed to or beyond their enrolment targets, and it has secured a commercial manufacturing agreement designed to scale US supply to hundreds of thousands of doses annually by later in the decade.

The matched diagnostic-and-therapeutic (theranostic) design is a structural feature that, if validated by trial data and regulators, could allow the same targeting molecule to be used to both identify and treat disease. The recent board appointment adds commercial and diagnostics leadership experience at a time when the company is publicly emphasising its commercialisation pathway. Collectively, these developments point to a company advancing from clinical development toward a potential product launch, though none of them guarantees regulatory approval or commercial success.

Material risks, uncertainties and investor considerations

Clarity remains a clinical-stage company, and the risks are significant. Its diagnostic has not yet received FDA marketing approval; Phase III enrolment completion does not assure positive topline results, and positive results do not assure approval. Regulatory timelines can slip, and requirements can change.

Radiopharmaceutical manufacturing and distribution are logistically demanding given short isotope half-lives, and planned capacity, such as the Pennsylvania facility slated for 2028, remains subject to construction, commissioning and execution risk. Commercial terms of the manufacturing agreement were not fully disclosed. Even upon approval, the company would face competition from established PSMA imaging agents already on the market, as well as pricing, reimbursement and adoption hurdles.

What investors may watch next

Key items that verified sources suggest could shape sentiment include topline data readouts from the CLARIFY and AMPLIFY Phase III trials, any subsequent FDA regulatory submission and its progress, and updates on the Nucleus RadioPharma manufacturing build-out toward commercial supply. Presentations of clinical data at scientific congresses such as EANM may also provide additional evidence on the candidate's diagnostic performance. On the corporate side, investors may monitor the company's cash position and any capital-management decisions. As always, the timing and outcomes of these events are uncertain.